Sinonasal Chondrosarcoma: An Analysis of the National Cancer Database

Introduction: Primary sinonasal chondrosarcoma is an indolent, locally aggressive malignancy that is thought to rise from the cartilaginous nasal septum. Due to its rarity, there are few large studies examining this entity. In this work, we describe the incidence and predictors of survival using the National Cancer Database (NCDB).

Methods: This was a retrospective, population-based cohort study of patients diagnosed with sinonasal chondrosarcoma between 2004 and 2016 in the NCDB. The primary outcome measure was overall survival (OS). Multivariate cox regression analysis was used to evaluate factors contributing to OS.

Results: A total of 78 patients met inclusion criteria. 37% of the cohort were male. The average age at diagnosis was 50.9 years. 88.5% of patients were white. Nasal cavity was the most common subsite (65.4%). No patients presented with metastatic disease. 61.5% underwent surgery alone, while 28.2% underwent surgery followed by adjuvant radiation. The 1-, 2-, and 5-year OS rates were 92.2, 80.4, and 49.9%, respectively. On multivariate analysis, no insurance (hazard ratio [HR]: 596; 95% confidence interval [CI]: 4.41–80.630) was associated with worse OS, while patients with Grade II—moderate differentiation tumors (HR: 0.27; 95% CI: 0.07–0.98)—had improved OS.

Discussion: Sinonasal chondrosarcoma is a rare malignancy with a 5-year survival nearing 50%. Most patients undergo either surgery or surgery followed by radiation. Insurance status and tumor grade are associated with survival.

 

Scroll to top

No conflict of interest has been declared by the author(s).

Publication History

Article published online:
15 February 2022